PL3263133T3 - Związek pirydynonu i jego zastosowanie - Google Patents
Związek pirydynonu i jego zastosowanieInfo
- Publication number
- PL3263133T3 PL3263133T3 PL16755729T PL16755729T PL3263133T3 PL 3263133 T3 PL3263133 T3 PL 3263133T3 PL 16755729 T PL16755729 T PL 16755729T PL 16755729 T PL16755729 T PL 16755729T PL 3263133 T3 PL3263133 T3 PL 3263133T3
- Authority
- PL
- Poland
- Prior art keywords
- pyridinone compound
- pyridinone
- compound
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4453—Non condensed piperidines, e.g. piperocaine only substituted in position 1, e.g. propipocaine, diperodon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/541—Non-condensed thiazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/15—Medicinal preparations ; Physical properties thereof, e.g. dissolubility
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Food Science & Technology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Toxicology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Oncology (AREA)
- Biophysics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2015039071 | 2015-02-27 | ||
PCT/JP2016/055927 WO2016136985A1 (ja) | 2015-02-27 | 2016-02-26 | ピリジノン化合物およびその用途 |
EP16755729.7A EP3263133B8 (en) | 2015-02-27 | 2016-02-26 | Pyridinone compound and use thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
PL3263133T3 true PL3263133T3 (pl) | 2020-10-05 |
Family
ID=56788708
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PL16755729T PL3263133T3 (pl) | 2015-02-27 | 2016-02-26 | Związek pirydynonu i jego zastosowanie |
Country Status (8)
Country | Link |
---|---|
US (2) | US10406141B2 (pl) |
EP (2) | EP3692992A1 (pl) |
JP (2) | JP6665155B2 (pl) |
DK (1) | DK3263133T3 (pl) |
ES (1) | ES2792989T3 (pl) |
PL (1) | PL3263133T3 (pl) |
PT (1) | PT3263133T (pl) |
WO (1) | WO2016136985A1 (pl) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3692992A1 (en) | 2015-02-27 | 2020-08-12 | Kyushu University National University Corporation | Method of screening dock1-selective inhibitors for cancer treatment |
WO2019173790A1 (en) * | 2018-03-09 | 2019-09-12 | Timothy Hla | Pyridinone- and pyridazinone-based compounds and medical uses thereof |
EP3888651A4 (en) | 2018-11-30 | 2023-01-18 | Kyushu University, National University Corporation | DOCK1 INHIBITING COMPOUND AND USE THEREOF |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US1000423A (en) * | 1911-01-05 | 1911-08-15 | Otto B May | Solid oil-containing medicine. |
SE7600674L (sv) | 1975-02-05 | 1976-08-06 | Rohm & Haas | Fungicider |
JP3568522B2 (ja) * | 2002-11-26 | 2004-09-22 | 独立行政法人 科学技術振興機構 | リンパ球遊走に不可欠なdock2の機能ドメイン及び会合分子 |
JP4795352B2 (ja) | 2004-08-28 | 2011-10-19 | アストラゼネカ・アクチエボラーグ | ケモカイン受容体モジュレーターとしてのピリミジンスルホンアミド誘導体 |
EP2091947A2 (en) * | 2006-12-20 | 2009-08-26 | Takeda San Diego, Inc. | Glucokinase activators |
US20110319459A1 (en) | 2007-06-14 | 2011-12-29 | Osta Biotechnologies | Compounds and Methods for Treating Cancer and Diseases of the Central Nervous System |
EP2296653B1 (en) | 2008-06-03 | 2016-01-27 | Intermune, Inc. | Compounds and methods for treating inflammatory and fibrotic disorders |
WO2012157389A1 (ja) | 2011-05-16 | 2012-11-22 | 国立大学法人九州大学 | DOCK-Aサブファミリー分子によるRac活性化を制御する低分子化合物及びその用途 |
EP3692992A1 (en) | 2015-02-27 | 2020-08-12 | Kyushu University National University Corporation | Method of screening dock1-selective inhibitors for cancer treatment |
TW201906819A (zh) | 2017-05-25 | 2019-02-16 | 日商大正製藥股份有限公司 | 新穎之咪唑衍生物 |
-
2016
- 2016-02-26 EP EP20162312.1A patent/EP3692992A1/en not_active Withdrawn
- 2016-02-26 ES ES16755729T patent/ES2792989T3/es active Active
- 2016-02-26 US US15/553,762 patent/US10406141B2/en active Active
- 2016-02-26 PT PT167557297T patent/PT3263133T/pt unknown
- 2016-02-26 PL PL16755729T patent/PL3263133T3/pl unknown
- 2016-02-26 JP JP2017502531A patent/JP6665155B2/ja active Active
- 2016-02-26 WO PCT/JP2016/055927 patent/WO2016136985A1/ja active Application Filing
- 2016-02-26 EP EP16755729.7A patent/EP3263133B8/en active Active
- 2016-02-26 DK DK16755729.7T patent/DK3263133T3/da active
-
2019
- 2019-07-19 US US16/517,385 patent/US11311523B2/en active Active
- 2019-12-27 JP JP2019238590A patent/JP6869571B2/ja active Active
Also Published As
Publication number | Publication date |
---|---|
EP3263133A4 (en) | 2019-03-13 |
EP3692992A1 (en) | 2020-08-12 |
EP3263133B1 (en) | 2020-04-01 |
JP6869571B2 (ja) | 2021-05-12 |
WO2016136985A1 (ja) | 2016-09-01 |
DK3263133T3 (da) | 2020-06-08 |
ES2792989T3 (es) | 2020-11-12 |
JP2020072706A (ja) | 2020-05-14 |
US20180028515A1 (en) | 2018-02-01 |
EP3263133A1 (en) | 2018-01-03 |
US20200061039A1 (en) | 2020-02-27 |
EP3263133B8 (en) | 2020-07-15 |
US11311523B2 (en) | 2022-04-26 |
US10406141B2 (en) | 2019-09-10 |
PT3263133T (pt) | 2020-05-21 |
JPWO2016136985A1 (ja) | 2018-01-11 |
JP6665155B2 (ja) | 2020-03-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1243741A1 (zh) | 腫瘤壞死因子受體超家族(tnfrsf)結合劑 | |
IL255577B (en) | Binding materials - tigit and their uses | |
SG11201706029VA (en) | Anti-senescence compounds and uses thereof | |
HK1256417A1 (zh) | 氰基噻吩並三唑並二氮雜環庚三烯及其用途 | |
HK1246780A1 (zh) | 氮雜-吡啶酮化合物及其用途 | |
ZA201705456B (en) | Benzoxaborole compounds and uses thereof | |
GB201608779D0 (en) | Methods and compounds | |
GB201504763D0 (en) | Compounds and uses | |
GB201616439D0 (en) | Compounds and uses | |
GB201608776D0 (en) | Methods and compounds | |
GB201507753D0 (en) | New compounds and uses | |
IL254241A0 (en) | Etv2 and its uses | |
IL253459B (en) | Isoergoline compounds and their uses | |
PT3263133T (pt) | Composto de piridinona e a sua utilização | |
GB201718875D0 (en) | Autophagy-inhibiting compounds and uses thereof | |
GB201614224D0 (en) | Compounds and uses thereof | |
IL265617B (en) | 1-phenylpropanone compounds and their use | |
HUE050178T2 (hu) | Piridinon vegyület és alkalmazása | |
IL258458B (en) | Peroxyhemiacetal profragrant and proflavor compounds | |
GB2543375B (en) | Compounds and their uses | |
GB2545167B (en) | Cloches and use thereof | |
GB201614874D0 (en) | New compounds and uses | |
GB201514770D0 (en) | Compounds and their use | |
GB201602572D0 (en) | New compound and uses | |
GB201507752D0 (en) | New compounds and uses |